Clinical efficacy and safety of TACE combined with lenvatinib and PD-1 antibody in treatment of intermediate-advanced hepatocellular carcinoma
10.16016/j.2097-0927.202405116
- VernacularTitle:TACE联合仑伐替尼及PD-1单抗治疗中晚期肝细胞癌的疗效及安全性分析
- Author:
Jiayun JIANG
1
;
Hui ZHANG
;
Shiyu ZHANG
;
Jiejuan LAI
;
Yanjiao OU
;
Leida ZHANG
Author Information
1. 400038 重庆,陆军军医大学(第三军医大学)第一附属医院肝胆外科
- Keywords:
hepatocellular carcinoma;
lenvatinib;
immunotherapy;
PD-1 antibody
- From:
Journal of Army Medical University
2024;46(22):2529-2538
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical efficacy and safety of transcatheter arterial chemoembolization(TACE)combined with lenvatinib and PD-1 antibody in the treatment of intermediate-advanced hepatocellular carcinoma(HCC).Methods A retrospective cohort trial was conducted on 105 patients with intermediate-advanced HCC(BCLC B or C stage)treated with TACE combined with lenvatinib and PD-1 antibody in our institute from January 2021 to June 2023.The blood biochemical indicators and imaging characteristics of the patients were collected before and after TACE.Objective response rate(ORR),disease control rate(DCR),conversion resection rate,overall survival(OS)and progression-free survival(PFS)were analyzed to evaluate the clinical efficacy of the triple therapy,and the frequency and severity of all adverse reactions during treatment were recorded to evaluate the safety of the therapy.Results Among the 105 patients with intermediate-advanced HCC who received triple therapy,33 died and 72 survived.The ORR was 62.8％and the DCR was 72.3％.The conversion resection rate was 11.4％.The median OS(mOS)was not reached.The median PFS(mPFS)was(10.3±0.8)months.The incidence of adverse reactions of all grades was 97.1％,and the incidence of those of grade 3～4 was 33.3％.No treatment-related death occurred.Conclusion The triple therapy of TACE combined with lenvatinib and PD-1 antibody is a safe and effective comprehensive treatment regimen,which provides a new treatment strategy for improving the prognosis of intermediate-advanced HCC.
